retatrutide trial status (Triple-Action Jab): Phase III results published in The Lancet reveal that this triple-hormone receptor agonist (targeting GLP-1, GIP, and glucagon receptors) achieves unprecedented Eli Lilly's Phase 3 clinical

Today, theyre widely prescribed for weight loss, cardiovascular risk reduction, and emerging indications such as sleep apnea, PCOS, and non-alcoholic fatty liver disease (NAFLD)

Many have found that their health insurance will not cover its use for weight loss

But, when kept active for hours, it can shut down food noise (constantly thinking about and desiring food) and hunger, slow digestion, and increase fullness

It's about: How your body processes food and stores fat

While more research is needed, the evidence so far suggests that GLP-1 medications may do more than just regulate metabolismthey could actively protect the brain from aging-related decline